How did ELEV's expenses impact profits in Q4 2024?

Elevation Oncology's expenses had a significant impact on profits in Q4 2024, with the company reporting a quarterly loss of $10.44 million.

1. Operating Expenses and Gross Margin: Specific figures for operating expenses and gross margin for Q4 2024 are not available. However, the fact that the company reported a loss suggests that expenses exceeded revenues in the quarter.
2. Net Margin: The net margin, which is the ratio of net income to total revenue, was negative for ELEV in Q4 2024, indicating that the company's expenses were greater than its revenues during the period.
3. Diluted EPS: The diluted EPS was also negative at $0.18 per share, further confirming that the company's expenses had a significant impact on profits in the quarter.

In summary, Elevation Oncology's expenses had a detrimental effect on profits in Q4 2024, with the company reporting a substantial quarterly loss. The lack of specific data on operating expenses and gross margin makes it difficult to provide a more detailed analysis, but the negative net margin and diluted EPS indicate that the company's costs were significantly higher than its revenues during the period.